摘要
同种异体造血干细胞移植是对称为Fanconi贫血(FA)的非恶性骨髓衰竭综合征的患者的唯一治疗性治疗。 然而,与这种方法相关的早期和晚期并发症强调了对替代治疗的需要。 旨在纠正患者自身造血干细胞中的遗传缺陷的基因治疗方法仍然是克服FA相关的骨髓衰竭的最有希望的策略。 然而,尽管二十多年的临床研究,治疗“成功”还没有实现。 在这里我们审查迄今为止进行的临床试验,并突出显示这些研究揭示的FA的独特功能。 这些功能使FA成为造血干细胞基因治疗方法的“圣杯”,并确定在这种罕见疾病中实现临床成功所需的未来步骤。
关键词: Fanconi贫血,临床试验,基因治疗,骨髓衰竭,干细胞,病毒载体。
Current Gene Therapy
Title:Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia
Volume: 16 Issue: 5
关键词: Fanconi贫血,临床试验,基因治疗,骨髓衰竭,干细胞,病毒载体。
摘要: Allogeneic hematopoietic stem cell transplantation is the only curative treatment for patients with the non-malignant bone marrow failure syndrome called Fanconi anemia (FA). However, early and late complications associated with this approach underscore the need for alternative treatments. Gene therapy approaches aiming to correct the genetic defect in the patient’s own hematopoietic stem cells remain the most promising strategy to overcome FA-associated bone marrow failure. Yet, despite more than two decades of clinical research, a therapeutic “success” has not yet been achieved. Here we review the clinical trials conducted to date and highlight the unique features of FA revealed by these studies. These features render FA the “holy grail” of hematopoietic stem cell gene therapy approaches, and identify the future steps required to achieve clinical success in this rare disease.
Export Options
About this article
Cite this article as:
Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia, Current Gene Therapy 2016; 16 (5) . https://dx.doi.org/10.2174/1566523217666170119113029
DOI https://dx.doi.org/10.2174/1566523217666170119113029 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteomic Identification of a Monoclonal Antibody Recognizing Caveolin-1 in Hepatocellular Carcinoma with Metastatic Potential
Protein & Peptide Letters The Role of Chemotherapy and Radiation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Dehydroleucodine Induces a TP73-dependent Transcriptional Regulation of Multiple Cell Death Target Genes in Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry The Efficacy of Vitamin K, A Member Of Naphthoquinones in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Current Cancer Drug Targets Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Pseudogene PTENP1 Suppresses Gastric Cancer Progression by Modulating PTEN
Anti-Cancer Agents in Medicinal Chemistry Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry HPV and Therapeutic Vaccines: Where are We in 2010?
Current Cancer Therapy Reviews Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry Transdermal Drug Delivery: A Step towards Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets Reducing radiation in chronic total occlusion percutaneous coronary interventions
Current Cardiology Reviews Topical Delivery of Drugs for the Effective Treatment of Fungal Infections of Skin
Current Pharmaceutical Design Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease
Current Topics in Medicinal Chemistry Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Current Pharmaceutical Design Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets